Everolimus Tablets For Oral Suspension and Viramune XR
Determining the interaction of Everolimus Tablets For Oral Suspension and Viramune XR and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Nevirapine may reduce the blood levels of everolimus in some patients, which may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the blood concentrations and pharmacologic effects of everolimus. In a study of healthy volunteers, multiple doses of the potent inducer rifampin increased the oral clearance of everolimus by threefold, representing mean decreases in peak blood concentration (Cmax) and systemic exposure (AUC) of 58% and 63%, respectively. The extent to which other inducers of CYP450 3A4 interact with everolimus is unknown.
MANAGEMENT: Some manufacturers recommend avoiding concomitant use of everolimus with moderate CYP450 3A4 and/or P-gp inducers such as bosentan, efavirenz, and nevirapine. If concomitant use is required, a dose adjustment of everolimus should be considered to achieve the recommended therapeutic range for the condition being treated. Please refer to the manufacturer's labeling for specific dosing information. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase and 2 weeks after discontinuation of the inducer.
- "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: everolimus
Brand name: Zortress, Afinitor, Afinitor Disperz
Synonyms: Everolimus
Generic Name: nevirapine
Brand name: Viramune, Viramune XR
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Everolimus Tablets For Oral Suspension-Virasal
- Everolimus Tablets For Oral Suspension-Virasal Topical
- Everolimus Tablets For Oral Suspension-Viravan P
- Everolimus Tablets For Oral Suspension-Viravan PDM
- Everolimus Tablets For Oral Suspension-Virazole
- Everolimus Tablets For Oral Suspension-Viread
- Viramune XR-Evista
- Viramune XR-Evoclin
- Viramune XR-Evoclin Topical
- Viramune XR-Evomela
- Viramune XR-Evotaz
- Viramune XR-Evoxac